Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BHVN. Cantor Fitzgerald cut shares of Biohaven Pharmaceutical from an "overweight" rating to a "neutral" rating in a research report on Wednesday, May 11th. SVB Leerink lowered Biohaven Pharmaceutical from an "outperform" rating to a "market perform" rating and set a $150.00 target price on the stock. in a research report on Wednesday, May 11th. Wedbush downgraded Biohaven Pharmaceutical from an "outperform" rating to a "neutral" rating and set a $148.50 price target for the company. in a report on Monday. HC Wainwright cut shares of Biohaven Pharmaceutical from a "buy" rating to a "neutral" rating in a report on Wednesday, May 11th. Finally, Piper Sandler lowered their target price on shares of Biohaven Pharmaceutical from $156.00 to $149.00 and set a "na" rating for the company in a report on Tuesday, May 24th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Biohaven Pharmaceutical presently has a consensus rating of "Hold" and a consensus target price of $157.17.

Biohaven Pharmaceutical Stock Down 0.2 %

NYSE:BHVN traded down $0.24 during trading hours on Wednesday, reaching $147.11. 648,322 shares of the company's stock were exchanged, compared to its average volume of 1,103,674. The firm has a market capitalization of $10.38 billion, a price-to-earnings ratio of -9.93 and a beta of 1.03. Biohaven Pharmaceutical has a 1-year low of $79.01 and a 1-year high of $151.51. The company has a 50-day moving average of $145.48 and a 200 day moving average of $130.61.

Biohaven Pharmaceutical (NYSE:BHVN - Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($2.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.52) by ($0.45). The company had revenue of $318.85 million during the quarter, compared to analysts' expectations of $187.12 million. During the same quarter in the prior year, the company posted ($4.21) earnings per share. Research analysts forecast that Biohaven Pharmaceutical will post -10.51 EPS for the current fiscal year.